Steve Thorne

Steve Thorne currently serves as Chief Scientific Officer of Kalivir and Western Oncolytics. He has many years of experience in the field of cancer immunotherapy, from discovery through clinical testing. As an entrepreneur, he has founded and co-founded several companies, including Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials, Western Oncolytics, Kalivir and Bioeclipse. Steve was previously a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London.